Drug intelligence / Profile preview

3-O-methylquercetin

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal, Oral

Overview

3-O-methylquercetin is a mono-methylated derivative of the flavonoid quercetin that exhibits potent antiproliferative activity against colorectal cancer (CRC) cells. It functions by inducing cell cycle arrest and apoptosis through the promotion of oxidative stress and mitochondrial dysfunction. Its molecular mechanism involves the inactivation of the SRC/JAK2/STAT3 signaling pathway, which is frequently overactive in various malignancies. Research indicates that 3-O-methylquercetin possesses selective cytotoxicity, targeting CRC cells while sparing normal human colon cells, making it a promising candidate for targeted cancer therapy.

Other names: 3-methylquercetin3-methoxyquercetin3-O-Methylquercetin

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on 3-O-methylquercetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-O-methylquercetin.

Explore the full profile